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Abstract
The gut microbiome consists of bacteria, protozoans, viruses, and archaea 
collectively called as gut microbiota. Gut microbiome (GM) modulates a variety of 
physiological responses ranging from immune and inflammatory responses, neu-
ronal signalling, gut barrier integrity and mobility, synthesis of vitamins, steroid 
hormones, neurotransmitters to metabolism of branched-chain aromatic amino 
acids, bile salts, and drugs. Type 2 diabetes mellitus (T2D) is a highly prevalent 
metabolic disorder that is featured by imbalance in blood glucose level, altered lipid 
profile, and their deleterious consequences. GM dysbiosis a major factor behind 
the incidence and progression of insulin resistance and is responsible for altering 
of intestinal barrier functions, host metabolic, and signaling pathways. The GM of 
type 2 diabetes (T2DM) patients is characterized by reduced levels of Firmicutes 
and Clostridia and an increased ratio of Bacteroidetes:Firmicutes. Endotoxemia 
stimulates a low-grade inflammatory response, which is known to trigger T2DM. 
Xenobiotics including dietary components, antibiotics, and nonsteroidal anti-
inflammatory drugs strongly affect the gut microbial composition and can promote 
dysbiosis. However, the exact mechanisms behind the dynamics of gut microbes 
and their impact on host metabolism are yet to be deciphered. Interventions that 
can restore equilibrium in the GM have beneficial effects and can improve glycemic 
control.
Keywords: type 2 diabetes, inflammation, immune response, gut microbiome, 
xenobiotics
1. Introduction
Our quality of life and health status are modulated by our food habits and 
lifestyle. Hence several metabolic disorders and are the greatest global health 
issues are influenced by improper diet and lifestyle [1]. The other factors that are 
involved in the development of metabolic disorders and diseases are environmental 
factors, maternal health, and host genetic makeup. The resident microorganisms 
in our gastrointestinal tract are collectively collected as the gut microbiota (GM). 
GM consists of bacteria, fungi, Archaea, protozoa, and viruses. In case of mam-
mals, GM comprises of four main phyla: Firmicutes (64%), Bacteroidetes (23%), 
Proteobacteria (8%), and Actinobacteria (3%). These phyla are important for the 
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regulation of host metabolism and physiology [2]. The total number of both pro-
karyotic cells and host eukaryotic cells in the gut is approximately 100 trillion, which 
is three times that of the total number of human body cells [3]. Hence, our unique 
gut environment is considered as a functional and measurable organ [4]. However, 
the composition of GM varies along the gastrointestinal tract, and differs within and 
between individuals depending on the gestational age, mode of delivery, breastfeed-
ing, antibiotic exposure, dietary lifestyle and nutritional status of the individual 
status of [5, 6]. The colonization of GM is limited in stomach and small intestine, 
but quite dense and diverse in the colon owing to the absence of digestive secretions, 
slow peristalsis, and rich nutrient supply [7]. This variety in composition of GM and 
its function is influenced by the consumption of improper diet, which in turn affects 
the health condition of the host. GM regulates the energy homeostasis, intestinal 
integrity and immunity against invading pathogens by participating in the digestive 
process and energy production, hampering pathogen colonization, and modulating 
the immune system; hence GM can modulate the overall health status of the host. 
Gut microbiome also influences an individual’s metabolic status such as calorie 
derived from indigestible dietary substances and storage of calories in adipose 
tissue, which regulates incidence of obesity in an individual. Studies from germ-free 
and wild type mice showed alteration in homeostasis in kidney, liver, and intestine 
in germ-free mice depicting the fact that GM influences whole body metabolism 
[8–13]. GM also plays a vital role in vitamin production, energy harvest and storage, 
fermentation and absorption of undigested carbohydrates. The distribution of GM 
is determined by diet to a large extent as evident from individuals who follow a diet 
high in animal fat have dominance of Bacteroides in GM, whereas those who follow a 
carbohydrate-rich diet have a Prevotella dominant GM (Table 1) [14–16]. According 
to conventional theories the relationship between genetic and environmental factors 
such as high-calorie diet and lack of physical activities was considered as the major 
main contributor to obesity but recently GM has attracted much attention in relation 
to human health and disease. Recent scientific investigations have shown that GM 
can be considered as an important endogenous factor controlling obesity [17, 18].
2. Host-gut microbiota metabolite interaction
Several reports have shown that the metabolites derived by GM from fermenta-
tion of food play a key role in maintenance of the host metabolism. Clostridium and 
Eubacterium from our GM break down bile acid in the intestine to its secondary 
metabolites like deoxycholic acid and lithocholic acid. These metabolites bind to 
Takeda G protein coupled receptor-5 TGR5 receptor (G-protein-coupled bile recep-
tor) present in the endocrine glands, adipocytes, muscles, immune organs, spinal 
cord and enteric nervous system, and stimulates the secretion of incretin hormone 
GLP-1 and insulin. Hence these metabolites in turn promote energy expenditure 
(Table 1) [19]. Long chain fatty acids, for example linoleic acid produced by the 
GM regulates our lipid profile finally resulting in obesity [20]. Short chain fatty 
acids (SCFs) another secondary metabolite of gut microbial fermentation is formed 
by the digestion of indigestible polysaccharides and oligosaccharides that are 
neither digested nor absorbed in the proximal jejunum [21]. SCFs mainly acetate 
and propionate contributed by Bacteroidetes and butyrate produced by Firmicutes 
balance the host metabolism by influencing energy homeostasis, lipid accumula-
tion and appetite [22]. SCF produced in the gastrointestinal tract are also known 
to control the pH of the lumen by increasing the absorption of nutrients. SCFs also 
act as a source of nutrition for GM due to high carbon content [23]. Butyrate is the 
main source of energy for colonocytes. It aids in the proliferation, maturation, 
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maintenance of colonocytes and also protects the colon by enhancing mucin expres-
sion and immune response [24]. Acetate and propionate can cross the liver epi-
thelium, and propionate gets metabolized in the liver, whereas acetate stays in the 
peripheral circulation [25]. SCF also regulates epithelial barrier integrity by main-
taining the tight junction proteins like claudin-1, occludin, and Zonula Occludens-1. 
Suppression of these proteins leads to invasion of bacteria and lipopolysaccharides 
(LPS) stimulating an inflammatory response [26]. Hence SCF acts as energy source 
and also regulates host biological responses including inflammation, oxidative 
Gut microbiota Facts and effects
Bifidobacteria Population reduces in high fat-fed mice gut increasing 
endotoxemia [14]
Bacteroidetes Population high in the gut of people consuming animal-based food 
rich diet [15]
Prevotella Population high in the gut of people consuming plant-based food 
rich diet [16]
Clostridium and Eubacterium Break down bile acid in the intestine to its secondary metabolites 
like deoxycholic acid and lithocholic acid. These metabolites bind 
to TGR5 receptor (G-protein-coupled receptor) present in the 
endocrine glands, adipocytes, muscles, immune organs, spinal cord 
and enteric nervous system, and stimulates the secretion of incretin 
hormone GLP-1 and insulin [19]
Lactobacillus reuteri GMNL-263 They are capable of reducing T2D markers like serum glucose, 
glycated hemoglobin and c-peptide in high-fructose-fed rats along 
with reduction in inflammatory cytokines IL-6 and TNF-α in adipose 
tissue and down-regulated forms of GLUT 4 and PPAR-γ [58]
Lactobacillus casei Shirota They can increase lipopolysaccharide-binding protein expression in 
plasma and diminishes endotoxemia [63]
Bifidobacterium animalis subsp. lactis They can restrict bacterial translocation in intestine alleviating 
bacteremia in early stages of T2D [64]
L. casei Zhang Oral administration can ameliorate impaired glucose tolerance in 
hyperinsulinemic rats induced by high-fructose [65]
Lactobacillus Oral administration is positively correlated with expression of CB2 
receptor [76]
Clostridium Oral administration is negatively correlated with CB2 expression 
probiotics control GM through CB2 receptor expression [76]
Bifidobacterium infantis Impairs inflammation by altering the intestinal permeability [80, 81]
Bacteroidetes:Firmicutes ratio Low in GM of obese patients [112, 113]
Butyrate-producing bacteria (Roseburia 
species and Faecalibacterium prausnitzii)
Low population in GM of T2DM patients [113]
Firmicutes (Gram-positive) and 
Bacteroidetes (Gram-negative)
90% of the bacterial species present in gut [15, 16]
Proteobacteria and particularly 
Escherichia coli
High in T2D patients [113, 121]
Enterobacteriaceae Population elevated by T2D drugs [122]
Clostridium and Eubacterium Population lowered by T2D drugs [122]
Akkermansia sp.
Akkermansia muciniphila
Metformin increases the populations of Akkermansia sp. in 
high-fat diet-fed mice, hence improving glucose metabolism. Oral 
administration of Akkermansia muciniphila also improves metabolic 
dysfunctions like endotoxemia and adipose tissue inflammation [122]
Table 1. 
Facts and effects of various types of bacteria present in GM
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stress, and immune response toward Crohn’s disease, ulcerative colitis, and colorec-
tal cancer [27, 28]. Host metabolism is activated by SCFs by direct stimulation 
of G-coupled receptors like free fatty acid receptors 2 and 3 (FFAR2/GPR41 and 
FFAR3/GPR41) occurring mainly in the gut epithelial cells. They also activate host 
metabolism by inhibiting nuclear class I histone deacetylases (HDACs) present in 
the epithelial cells [27]. FFAR2 acts as the receptor for acetate and FFAR3 is the 
receptor for butyrate and propionate. Activation of these receptors regulates the 
level of satiety hormones like ghrelin (orexigenic peptide), glucagon like peptide-1 
(GLP-1), and peptide YY (PYY) (anorexigenic peptide) [29]. Ghrelin secretion 
occurs pre-meal, while GLP-1 and PYY are secreted post-meal, which in turn stimu-
lates insulin production in the pancreatic 𝛽 cells. GLP-1 and PYY also reduce food 
intake, normalizes weight loss and maintain the balance of energy intake. Increase 
in the production of SCFs enhances the secretion of PYY and GLP-1 but decreases 
secretion of ghrelin, which ultimately leads to increased satiety and reduction 
in food intake [30]. The other factors inducing reduced appetite is mediated by 
butyrate and propionate by (i) enhanced expression of leptin in adipocytes, direct 
regulation of body weight and energy homeostasis by decreased food intake and 
upregulated energy expenditure [31], (ii) promoting gluconeogenesis in the intesti-
nal cells [32] and (iii) inhibition of histone acetyltransferase and deacetylases which 
exhibit anti-inflammatory responses, epigenetic modification necessary for prolif-
eration and differentiation of immune cells, activated AMP-activated protein kinase 
(AMPK) pathway synchronised adiponectin secretion, induction of mitochondrial 
biogenesis and fatty acid oxidation [33]. In healthy subjects SCF regulates integrity 
of gut, secretion of hormones, and immune responses, while in metabolically 
unhealthy subjects SCF implements protection from diabetes, ulcerative colitis, 
colorectal cancer, and neurodegenerative disorders [24, 34].
2.1 Gut microbiota composition
Recent studies targeting metagenomics have disclosed that approximately 
90% of the bacterial species in the GM of adult humans are Bacteroidetes (Gram-
negative) and Firmicutes (Gram-positive) [35, 36]. A healthy person fosters 
500–1000 bacterial species at a single time and almost 1012–1014 colony-forming 
units (CFU) with a total mass weight of about 1–2 kg in the total gut [37] with 
109–1012 CFU/ml in the colon, 101–103 CFU/ml in jejunum and 104–108 CFU/ml in 
the ileum [38]. Transfer of microbiota from mother to embryo takes place in utero 
or during birth and attains strength by the 2 years. Composition of GM is shaped by 
host genetics, environmental factors and early exposure to microbes during birth. 
The other factors that regulate formation of a stale GM are exposure to vaginal 
microbiome during normal delivery, skin microbiota during cesarean sections, 
breast-feeding and antibiotics in neonatal or early childhood.
2.2 Role of gut microbiota in carbohydrate metabolism
Normal diet of a healthy human contains a considerable percentage of carbohy-
drates comprising of monosaccharides, disaccharides and complex polysaccharides. 
The difference lies in the absorption of the sugars, for example common sugars like 
cane sugar and fruit sugars are readily absorbed in the intestine, disaccharides like 
maltose, lactose and sucrose and complex polysaccharides like pectin, starch and 
hemicellulose are broken down into monosaccharides in the ileum with the help of 
bacterial enzymes like glycosidases before being absorbed [39]. After food intake 
consisting of carbohydrate-rich diet, glucose levels in the blood rise, and later are 
strongly regulated and kept at a homeostatic level by the help of two hormones, 
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insulin and glucagon. Carbohydrate digestion and absorption occurs in the upper 
digestive tract via glucose transporters called GLUTs (glucose transporters) located 
on the epithelial cells [40]. GLUT proteins uptake glucose into the pancreatic 
β-cells. Metabolization of glucose stimulates insulin secretion due to increased ATP/
ADP ratio, membrane depolarization and closure of potassium channels, resulting 
in calcium dependant exocytosis of insulin [41].
The role of gut environment and gut associated lymphoid tissue plays a pivotal 
role in T2D [42]. T2D is a chronic metabolic disorder characterized by fasting 
serum hyperglycemia, non-responsiveness of insulin and insulin insufficiency [43]. 
Insulin resistance or non-responsiveness occurs in the liver and skeletal muscle cells 
when they undergo failure to sense insulin. Other factors in T2D are non-respon-
siveness or deficiency of incretins, amplified lipid catabolism, increased glucagon 
levels in circulation and increased salt and water renal retention [43, 44]. High-fat-
diet-fed germ-free mice, wild type mice and standard diet fed mice exhibit different 
metabolic and immunological characters depending on diet and GM [45, 46]. Also 
mice belonging to same genotype and diet exhibit different metabolism of glucose 
depending on their GM [47].
2.3 Role of gut microbiota and its association with diet
In the earlier sections it has been discusses that our GM plays a key role in diges-
tion and absorption of food. Increased population of Bacteroidetes lead to increase 
in energy production. The population of Bifidobacteria reduce in high fat-fed mice 
gut increasing endotoxemia. Prebiotic supplementation can restore Bifidobacteria 
levels in the mouse gut [48, 49]. Bacteroidetes are more widespread in the gut of 
people consuming animal-based food rich diet. Prevotella is prevalent in people 
consuming plant-based food rich diet. In case of people consuming plant-based 
foods, the GM produce more SCFAs and increased synthesis of amylase, glutamate 
and riboflavin [50, 51]. On the contrary, people consuming animal-based foods 
have GM modified for increased catabolic processes as for example degradation of 
glycans and amino acids [52]. SCFAs like butyrate, propionate and acetate along 
with some gases like hydrogen are produced by the breakdown of these polysaccha-
rides, are further used in colonic fermentation and yield energy [53]. Butyrates can 
decrease calorie intake of an individual by inducing satiety via production of GLP-1 
and gastric inhibitory peptide-1 [54]. Butyrates are also involved in maintenance 
of gut integrity by supplying energy for regulating the survival and proliferation of 
enterocytes.
Low-grade inflammation is a key pathophysiological factor behind the progres-
sion of type 2 diabetes (T2D), and incidence of hyperglycemia and insulin resistance 
[55]. Progression of T2D occurs along with reduced GM diversity and increased gut 
inflammation. Gut inflammation includes innate immune responses via toll-like 
receptors, (TLRs) secretion of proinflammatory cytokines and increased endotox-
emia. Also during high-fat diet induced obesity, intestinal Gram-negative bacteria 
translocates in the circulatory system, adipose tissue and cause endotoxemia [56].
2.4 Role of probiotics upon gut microbiota
Probiotics enhance production of interleukin-10 (IL-10) an important regula-
tory and anti-inflammatory cytokine in diabetic mice. Increased IL-10 down-
regulates proinflammatory cytokines like interferon-γ (IFN-γ) and interleukin-2 
(IL-2)/interleukin 1-β (IL-1β) preventing inflammation and incidence of diabetes 
[56, 57]. Lactobacillus reuteri GMNL-263 reduces T2D markers like serum glucose, 
glycated hemoglobin and c-peptide in high-fructose-fed rats along with reduction 
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Figure 1. 
Influence of gut microbiota in various physiological responses [80, 81, 83, 84, 110, 111].
in inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-α 
(TNF-α) in adipose tissue and down-regulated forms of GLUT 4 and peroxisome 
proliferator activated receptor-γ (PPAR-γ) (Figure 1 and Table 1) [58]. Methodical 
consumption of probiotic yoghurt reduces inflammatory markers such as high-
sensitivity C-reactive protein levels in pregnant women and T2D [59, 60]. Probiotic 
strains decrease oxidative stress in pancreatic tissue, reducing inflammation and 
apoptosis of pancreatic cells [61]. Probiotic strains also lessen LDL cholesterol 
and total cholesterol in serum by regulating lipid metabolism, reducing the risk of 
T2D [62]. Consumption of Lactobacillus casei Shirota increase lipopolysaccharide-
binding protein expression in plasma and diminishing endotoxemia (Table 1) [63]. 
Bifidobacterium animalis sub sp. lactis can restrict bacterial translocation in intes-
tine alleviating bacteremia in early stages of T2D (Table 1) [64]. Oral administra-
tion of L. casei can also ameliorate impaired glucose tolerance in hyperinsulinemic 
rats induced by high-fructose (Table 1) [65].
2.5  Role of gut microbiota in maintaining intestinal integrity and metabolic 
conditions
Increased gut permeability provides the relation between high-fat diet and LPS 
by causing LPS entry into circulation via the portal system in T2D patients [66]. 
Animal model studies have provided evidence between increased intestinal perme-
ability and progression of obesity and insulin resistance [67, 68]. Consumption 
of prebiotics increase gut microbiota, rectify intestinal permeability, diminish 
inflammation, alleviate endotoxemia and ameliorate glucose tolerance [68]. High-
fat diet induce decrease in tight junction proteins regulating epithelial integrity of 
gut lining and gut permeability such as zonula occluden-1 (ZO-1) and occludin. 
Dietary fatty acids activate toll-like receptor 2 (TLR-2) and toll like receptor 4 
(TLR-4) signaling pathways. TLR-4 leads to LPS translocation into intestinal 
capillaries and induces insulin resistance in mice [69–71]. Altered gut permeability 
and plasma LPS levels are related with distribution of ZO-1 and occluding and 
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endocannabinoid (eCB) system. Gut microbes selectively modify expression of 
the cannabinoid receptor 1 (CB1) in colon also affecting zona occluding ZO-1 and 
occludin [72]. Administration of probiotics changes the gut microbiota resulting 
in reduced gut permeability in obese mice. Antibiotic exposure induces metabolic 
endotoxemia in mice fed with high-fat diet, along with increased gut permeability, 
secretion of proinflammatory cytokines, and incidence of diabetes and obesity 
(Figure 1). Modulation of the eCB system is connected with inflammation and 
diabetes [72, 73]. Moderation of GM controls eCB expression in gut, thereby 
regulating gut permeability and plasma LPS levels through the CB1 receptor [72]. 
Changes in the gut microbiota due to prebiotic feeding reduce gut permeability 
in obese mice. Modulation of gut permeability occurs through the distribution 
of tight junction proteins through eCB systems [55]. Activation of cannabinoid 
CB2 receptor and blocking of CB1 receptor improves glucose tolerance [74, 75]. 
Lactobacillus administration is positively correlated with expression of CB2 recep-
tor, and Clostridium spp. is negatively correlated with CB2 expression (Table 1) 
[76]. Also probiotics control GM through CB2 receptor expression [77].
3. Gut microbiota and obesity mediated type 2 diabetes
GM has a close association with host obesity, since the increase in total body fat 
in wild type mice is high when compared to germ free mice consuming more food. 
Transplanting of cecum-derived microbiota induced an increase in body fat mass 
and insulin resistance, adipocyte hypertrophy, and increased level of circulating 
leptin and glucose [78]. Germ free mice when fed with a diet rich in fat and sugar 
content showed lean phenotype however wild type mice who were fed with the high 
sugar and high fat diet turned obese. Also the germ free mice showed enhanced 
insulin sensitivity, leading to improved glucose tolerance and altered cholesterol 
metabolism diminishing cholesterol storage and increasing cholesterol excretion via 
fecal route. GM alters intestinal permeability, causes endotoxemia, enhances calorie 
provision, stimulates endocannabinoid system (eCB), regulates lipid metabolism 
by increasing activity of lipoprotein lipase and lipogenesis resulting in host obesity. 
Lipopolysaccharides (LPS), present in the cell membrane of Gram-negative bac-
teria, stimulate low-grade inflammation and incidence of insulin resistance (IR). 
LPS reaches the circulation from gut by diffusion either by enhanced intestinal 
permeability or absorption after association with chylomicron [79]. LPS acts as a 
ligand for toll-like receptors TLR-4 occurring in immune cells, liver and adipose 
tissue. LPS activated TLR-4 prompts conformational changes recruiting adapter 
molecules like myeloid differentiation primary factor MyD88 protein, IL-1 receptor 
associated kinase IRAK, TNF receptor associated factor TRAF6, and NF-κB induc-
ing kinase NIK, phosphorylating and degrading inhibitor of nuclear factor kappa 
B kinase IKKB, inhibitor of nuclear factor kappa light chain enhancer of activated 
B cells NF-κB. Activated NF-κB translocates to the nucleus triggering expression of 
inflammatory proteins and various pathways like janus kinase JNK, p38 microtu-
bule associated protein kinase MAPK, and extracelluar signal regulated kinase ERK 
finally resulting in insulin resistance (Figure 1). Colonization of Bifidobacterium 
infantis can impair inflammation by altering the intestinal permeability. Excess of 
lipid in diet enhances exposure to free fatty acids and their derivatives, facilitates 
endotoxin absorption and increases plasma LPS level termed as “metabolic endo-
toxemia” (Table 1) [80, 81]. Interaction between endogenous lipid and cannabinoid 
receptor (CB1 and CB2) stimulates adenylate cyclase and MAPK, ERK, and NF-κB 
pathways, triggering inflammation, insulin resistance and obesity [82]. On the 
whole GM stimulates the eCB system, enhances intestinal permeability, triggering 
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LPS entry into circulatory system resulting in endotoxemia. Rise in LPS, modulates 
the integrity of the tight junctions of the intestinal membrane increasing LPS in 
circulation. Therefore, GM is a complex system having both advantageous and dan-
gerous microbes, and understanding the GM and host integration system provides a 
generalized idea about the function of each unit of the GM-host system [83, 84].
3.1 Gut microbiota and carbohydrate metabolism during type 2 diabetes
Bile acids affect glucose homeostasis via activation of nuclear farnesoid X 
receptor (FXR) and the membrane-bound G protein coupled receptor, TGR5. These 
receptors are expressed in liver, ileum and pancreas [85]. Some bile acids act as 
agonists for FXR, and others are FXR antagonists [86–88]. Known FXR agonists 
are CDCA, lithocholic acid, deoxycholic acid, and cholic acid [89]. The antidiabetic 
effects exhibited by vertical sleeve gastrectomy, bariatric surgery, occurs through 
FXR [90]. Also, intestinal FXR agonist treatment can improve insulin sensitivity 
[91]. In the ileum, activation of FXR leads to the production of fibroblast growth 
factor-19, a hormone that affects glucose tolerance through mechanisms that are 
largely independent of insulin [92, 93]. Activation of TGR5 produces glucagon-like 
peptide-1 (GLP-1) from ileum improves both energy and glucose homeostasis [94]. 
Activation of FXR in pancreas regulates insulin transport and secretion [95], and 
protects the islets from lipotoxicity [96]. FXR activation in liver improves insulin 
sensitivity in T2D patients [97]. The GM can modulate the amount and type of 
secondary bile acids produced via FXR and TGR5 signaling. GM enzymes such as 
bile salt hydrolase for deconjugation, 7-alpha dehydroxylase for dihydroxylation 
and 7α-hydroxysteroid dehydrogenase for epimerization of bile acids are reduced 
in T2D patients compared to healthy controls [98]. Bile acid concentrations in the 
circulation show a diurnal pattern since they increase after food intake [99].
3.2 Gut microbiota and lipid metabolism during type 2 diabetes
Our body metabolism, inflammatory processes and innate immune system are 
regulated by dietary lipids [100]. The dietary lipids can also act as (proinflamma-
tory) ligands which can bind to nuclear receptors [101]. The nuclear receptors are 
peroxisome-proliferator-activated receptors (PPAR) and liver X receptors (LXR) 
which regulate metabolic and inflammatory pathways. Hence the dietary lipids can 
improve insulin action and down-regulate secretion of pro-inflammatory cytokines 
[102, 103]. Lipids can also activate G-protein coupled receptors (Gpcr) such as Gpr43 
when activated by dietary-metabolite acetate lipolysis in adipocytes is decreased 
leading to reduced plasma-free fatty acids. Gpr43 can be considered as a potential 
target for regulation of lipid metabolism [104]. Inflammation and lipid accumula-
tion are characteristic features of atherosclerosis [105]. Recent evidences provide 
sufficient link between atherosclerosis and GM variety [106]. Short-term antibiotic 
administration can alter the composition of GM which can convert dietary choline 
and l-carnitine to trimethylamine (TMA). TMA is later oxidized into TMAO by the 
action of hepatic Flavin monooxygenases [107]. Dietary choline is highly available 
in foods rich in lipid phosphatidylcholine, lecithin, such as in eggs, red meat, milk, 
poultry, liver, and fish [108]. Bile acids are key modulators of lipid and cholesterol 
metabolism, and they facilitate intestinal absorption and transport of nutrients, 
vitamins, and lipids. Production of bile occurs in the liver and 95% of bile acids are 
reabsorbed in the ileum. Later the bile acids are re-absorbed in liver, entering the 
enterohepatic circulation. GM converts primary bile salts to secondary bile salts by 
bile acid de-hydroxylation [109]. Bile acids can also result in the release of GLP-1 
from enteroendocrine L cells via activation of Takeda G protein coupled receptor-5 
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(TGR5) (Figure 1). This phenomenon affects insulin secretion sensitivity [110]. 
Bile acids have another receptor called farnesoid X receptor (FXR) present in liver, 
intestine, and pancreatic beta cells [111]. Hence, bile acids improve our metabolism 
in the long term after bariatric surgery by enhancing intestinal hormone secretion.
3.3 Gut microbiota composition during type 2 diabetes
The GM of T2D patients exhibit low population of Firmicutes and Clostridia 
and high ratio of Bacteroidetes:Firmicutes (Table 1) [112, 113]. However, the GM 
of T2DM and obese patients are not always identical because the GM of obese 
patients show decreased Bacteroidetes:Firmicutes ratio [113–115, 118]. GM of 
T2DM patients also show low population of butyrate-producing bacteria. Short-
chain fatty acids (SCFAs) like butyrate, acetate, and propionate are fermented 
from dietary fiber in large intestine by GM. SCFAs regulate energy metabolism, 
immune responses and tumorigenesis in gut. Butyrate is the energy source for 
colonic epithelial cells. Butyrate perpetuates intestinal integrity and thereby avert 
translocation of Gram-negative intestinal bacteria across the lumen of the gut. This 
phenomenon ultimately leads to endotoxemia triggering a low-grade inflammation 
during T2D [15, 113, 115].
The major risk factors behind T2D are genetic predisposition, less physical 
activity, fetal programming, obesity and altered GM [114, 116]. Total weight of 
GM in the distal gut is about 1.5 kg and it is considered as a microbial organ. The 
GM consists of embers from Bacteria, Archaea, Eukarya and viruses, but a large 
part of the population includes anaerobic bacteria. 90% of the bacterial species 
present in gut are grouped into the two bacterial phyla Firmicutes (Gram-positive) 
and Bacteroidetes (Gram-negative) (Table 1) [15, 16]. An average adult fosters a 
minimum of 160 bacterial species and a set of genes in the GM is obligatory for 
proper functioning of the GM [15]. The GM gives protection from disease caus-
ing pathogens and facilitates the immune system. GM also help in production of 
vitamin K and many B-vitamins like folate, vitamin B12. Metagenomic studies 
about sequencing of T2D patients exhibit dysbiotic GM and less butyrate-producing 
bacteria (Roseburia species and Faecalibacterium prausnitzii). Metabolic disorders 
like obesity and impaired glucose metabolism are related with an altered ratio 
of Firmicutes and Bacteroidetes [118–120]. Populations of Proteobacteria and 
particularly Escherichia coli are also high in T2D patients (Table 1) [113, 121]. 
Gram-negative bacteria contribute to inflammatory lipopolysaccharides (LPS) 
stimulating pro-inflammation, during T2D and obesity. Oral administration of 
metformin, a widely used drug for T2D elevates populations of Enterobacteriaceae 
and lowers populations of Clostridium and Eubacterium. Metformin also increases 
the populations of Akkermansia sp. in high-fat diet-fed mice, hence improving 
glucose metabolism [122]. Oral administration of Akkermansia muciniphila also 
improves metabolic dysfunctions like endotoxemia and adipose tissue inflammation 
(Table 1) [122, 123]. Hence metformin can be used as a potent drug in improvising 
the GM content in T2D patients, managing glucose tolerance and inflammation.
4. Modulation of gut microbiota to cure type 2 diabetes
4.1 Antibiotics
Antibiotics have become very popular for elimination of pathogenic bacte-
ria. However, antibiotics are also harmful to the local population of beneficial 
GM. Hence excess use of antibiotics must be prevented for healthy maintenance of 
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GM. Bacterio-therapeutic use of antibiotics in farm animals has increased increase 
growth and food production, but has taken a toll of their metabolic pathways [115]. 
Excess of usage of antibiotics in early infancy show chronic effects on GM diversity, 
overweight in infants, obesity in adults. For example, excess of bacterio-therapy 
with vancomycin has increased the incidence of obesity in adults. Even, short-term 
treatment with vancomycin impeded peripheral insulin sensitivity and other related 
metabolic syndromes affecting GM (Table 2) [115]. Hence, even short-term treat-
ment with oral antibiotics harness intense and chronic damage to GM diversity and 
function.
4.2 Prebiotics and probiotics
Recently prebiotics and probiotics have gained a lot of popularity among 
individuals as a healthy substitute for antibiotics. Prebiotics are actually indigestible 
carbohydrates that improve the growth and function of colonic bacteria boosting 
host health. Prebiotics include oligosaccharides which cannot be digested in the 
upper GI tract. These oligosaccharides are fermented, producing SCFAs in the 
colon and result in stimulation of growth of colonic. Prebiotics can be obtained 
from a large number of dietary elements like barley, garlic, asparagus, wheat bran 
and onions and both prebiotics and probiotics can be obtained from pickled and 
fermented foods like sauerkraut, kimchi, miso, yogurt [15, 16]. Probiotics obtained 
from food and supplements contain some very popular strains like bifidobacteria 
and lactobacilli. These bacteria alter the composition and function of GM as well 
as host system activity. The prebiotics and probiotics compete with pathogenic 
Types of cure Effects
Antibiotics • Affect GM diversity
• Overweight in infant
• Obesity in adult
• Vancomycin impede insulin sensitivity [115]
Prebiotics and probiotics • Compete with pathogenic bacteria
• Intensify intestinal barrier by secreting some antimicrobial substances
• Enhances immune system [15, 16, 115]
Dietary modulation • Increase GM ecosystem diversity
• Enhances SCFA
• Reduces fasting and postprandial glucose, A1C, serum cholesterol, 
insulin resistance, BMI, waist and hip circumferences [124]
Metformin • Increases levels of butyrate-producing bacteria
• Decreases levels of Lactobacillus [125]
Fecal microbiota transplant • Allogenic infusion from lean donors lead to significant rise in GM 
diversity, enhanced levels of butyrate producing bacteria and improved 
insulin sensitivity [114, 115]
Bariatric surgery • Proteobacteria rises and Firmicutes and Bacteroides lowers
• BMI reduces by 15–32%
• C-reactive protein decreases
• T2DM is attenuated [112, 115]
Table 2. 
Types of treatments for T2D involving modulation of GM and their effects.
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bacteria, intensify the intestinal barrier by secreting some antimicrobial substances 
and enhances the immune system (Table 2) [15, 16, 115].
4.3 Dietary modulation
Changes in diet plan can modulate activity of GM and host metabolism. A fat 
and carbohydrate restricted diet increased the ratio of Bacteroidetes to Firmicutes 
in obese patients with T2D [118]. Also calorie deficient diet plans or diet plans 
rich in high-fiber macrobiotics like complex carbohydrates, legumes, fermented 
products, sea salt, and green tea and free of animal protein fat, and added sugar 
improved dysbiosis, increased GM ecosystem diversity, and enhanced SCFA 
producers in T2D patients. Macrobiotic diet can more efficiently reduce fasting and 
postprandial glucose, A1C, serum cholesterol, insulin resistance, BMI, waist and hip 
circumferences than the control diet. Also macrobiotic diet could effectively reduce 
pro-inflammatory bacterial strains (Table 2) [124].
4.4 Metformin
Metformin, already a well-established drug for T2D, has recently been known 
to have bacterio-therapeutic effects on microbial composition and production of 
SCFA. Several recent reports have shown that metformin affects GM of T2D patients 
like increasing the levels of butyrate-producing bacteria. Metformin can also decrease 
the levels of Lactobacillus which remains high in T2D patients (Table 2) [125].
4.5 Fecal microbiota transplant
Fecal microbiota transplant, or stool transplant also called bacteriotherapy, 
which is the process of replacing fecal bacteria from a healthy individual into a host 
individual has been quite effective in restoring GM composition. Fecal microbiota 
transplant is used in treating recurrent Clostridium difficile colitis recharging useful 
bacteria in the GI tract along with usage of antibiotics. Autologous infusion is 
reinfusion of one’s collected feces and allogenic infusion is infusion with feces from 
a donor. Insulin resistant adults when autologously transplanted did not alter the 
GM composition but when transplanted with allogenic infusion from lean donors 
exhibited significant rise in GM diversity, enhanced levels of butyrate producing 
bacteria and improved sensitivity to insulin (Table 2) [114, 115].
4.6 Bariatric surgery
Bariatric surgery, or Roux-en-Y gastric bypass (RYGBP), is removal of a portion 
of stomach and re-routing the small intestine to a small stomach pouch. It is per-
formed on people as an efficient tool to treat obesity. After bariatric surgery huge 
changes occur in the GM, Proteobacteria rises and Firmicutes and Bacteroides low-
ers, BMI reduces by 15–32%, C-reactive protein decreases and T2DM is attenuated. 
However, increase in some bacteria are highly significant than the normal levels in 
lean controls, which means these alterations are linked with GM modification, and 
not body weight (Table 2) [112, 117, 118].
5. Conclusion
The GM makes one of the largest organs in human body and remains the reason 
behind various metabolic disorders such as obesity, atherosclerosis, type 2 diabetes 
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and so on. The alterations in GM is very susceptible to changes in our diet and 
environment which makes them vulnerable and ultimately ends in the incidence of 
diseases. Reversal of the GM alterations can restore the normal physiological func-
tions and health. Hence further investigation is required in order to get a detailed 
scenario of the composition of various GM and their detailed function. Scrutiny of 
the composition of the GM and the change in their population in various metabolic 
disorders can create new avenues in finding out the treatment for those diseases. 
Deeper insights in the composition and function of GM can also provide more ideas 
for development of various techniques and drugs for the enhancement of the GM 
for better physiological responses and treatment of diseases.
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